Evidence map›Paper›PMID 38231342›Full record

ArticleJournal of epidemiology and global health2024

Familial Screening for the Prevention of Rare Diseases: A Focus on Lipodystrophy in Southern Saudi Arabia.

Adel Abuzenadah, Nofe Alganmi, Raghad AlQurashi, Esraa Hawsa, Abdullah AlOtibi, Abdulrahman Hummadi, Ahmed Ali Nahari, Somaya AlZelaye, Nasser R Aljuhani, Manal Al-Attas and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of epidemiology and global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Adel AbuzenadahFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Nofe AlganmiFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Raghad AlQurashiMolecular Genetics Laboratory, Public Health Laboratory, Public Health Authority, Riyadh, Saudi Arabia.
Esraa HawsaMolecular Genetics Laboratory, Public Health Laboratory, Public Health Authority, Riyadh, Saudi Arabia.
Abdullah AlOtibiMolecular Genetics Laboratory, Public Health Laboratory, Public Health Authority, Riyadh, Saudi Arabia.
Abdulrahman HummadiJazan Endocrinology and Diabetes Center, Ministry of Health, Jazan, Saudi Arabia.
Ahmed Ali NahariJazan Endocrinology and Diabetes Center, Ministry of Health, Jazan, Saudi Arabia.
Somaya AlZelayeCentre of Endocrinology and Diabetes Mellitus, Al-Qunfudah General Hospital, Al-Qunfudah, Makkah Province, Saudi Arabia.
Nasser R AljuhaniDepartment of Medicine Endocrinology and Diabetes, East Jeddah Hospital, Jeddah, Saudi Arabia.
Manal Al-AttasFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Heba AbusamraFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Shereen TurkistanyCenter of Innovation in Personalized Medicine, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Sajjad KarimFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Zeenat MirzaDepartment of Medical Lab Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Mohammed Al-QahtaniFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Adeel ChaudharyFaculty of Applied Medical Sciences, Center of Excellence in Genomic Medicine Research, King Abdulaziz University, 21589, Jeddah, Saudi Arabia.
Mariam M Al EissaMolecular Genetics Laboratory, Public Health Laboratory, Public Health Authority, Riyadh, Saudi Arabia. mmeissa@pha.gov.sa.
King Abdulaziz University · SAJazan University · SAKing Fahad Central Hospital · SAKing Fahad Hospital Jeddah · SA

Funding

Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia and King Abdulaziz University, DSR, Jeddah, Saudi Arabia. IFPNC-008-141-2020
6 · The paper itself

Abstract

backgroundLipodystrophy is a relatively rare, complex disease characterised by a deficiency of adipose tissue and can present as either generalised lipodystrophy (GLD) or partial lipodystrophy (PLD). The prevalence of this disease varies by region. This study aimed to identify the genetic variations associated with lipodystrophy in the southern part of Saudi Arabia. METHODOLOGY: We conducted a retrospective study by recruiting nine patients from six families, recruiting the proband whole exome sequencing results or any other genetic test results, screening other family members using Sanger sequencing and analysing the carrier status of the latter. These patients were recruited from the Endocrinology and Diabetes Clinic at Jazan General Hospital and East Jeddah Hospital, both in the Kingdom of Saudi Arabia.

resultEight patients were diagnosed with GLD, and one was diagnosed with PLD. Of the six families, four were consanguineously married from the same tribe, while the remaining belonged to the same clan. The majority of GLD patients had an AGPAT2 c.158del mutation, but some had a BSCL2 c.942dup mutation. The single PLD case had a PPARG c.1024C > T mutation but no family history of the disease. In all families evaluated in this study, some family members were confirmed to be carriers of the mutation observed in the corresponding patient.

conclusionFamilial screening of relatives of patients with rare, autosomal recessive diseases, such as lipodystrophy, especially when there is a family history, allows the implementation of measures to prevent the onset or reduced severity of disease and reduces the chances of the pathogenic allele being passed onto future generations. Creating a national registry of patients with genetic diseases and carriers of familial pathogenic alleles will allow the assessment of preventive measures and accelerate disease intervention via gene therapy.

Indexed as

Genetic TestingRare DiseasesAdolescentAdultChildExome SequencingFemaleHumansLipodystrophyMaleMiddle AgedMutationPedigreeRetrospective StudiesSaudi ArabiaYoung AdultCommon variantsLipodystrophyPreventionRare diseasesSaudi Arabia

Identifiers

PMID38231342
PMCPMC11043304
OpenAlexW4390954561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.